Teva Pharmaceutical Industries (TEVA)
(Delayed Data from NYSE)
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 5:48 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.46 USD
-0.21 (-1.19%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $17.41 -0.05 (-0.29%) 5:48 PM ET
3-Hold of 5 3
A Value B Growth C Momentum A VGM
Zacks News
Allergan (AGN) Beats on Q1 Earnings & Sales, Raises '19 View
by Zacks Equity Research
Allergan's (AGN) stock declines slightly in pre-market trading despite the company delivering earnings and revenue beat in the first quarter while marginally raising its guidance
Mylan (MYL) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Investors will focus on the performance of Wixela Inhub, the newly launched biosimilars and other updates from Mylan (MYL)'s pipeline when the company shortly reports Q1 results.
Teva (TEVA) Q1 Earnings Beat, Copaxone Drags Sales Down
by Zacks Equity Research
Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Blockbuster drug Copaxone sales continue to erode amid generic competition.
Teva (TEVA) Beats on Q1 Earnings, Misses Sales, Shares Down
by Kinjel Shah
Teva Pharmaceutical (TEVA) beats estimates for earnings but misses the same for sales. Shares decline in pre-market trading.
Lilly (LLY) Down Despite Q1 Earnings Beat on Sales View Cut
by Zacks Equity Research
Eli Lilly's (LLY) earnings beat estimates in Q1. Stock falls in pre-market trading as the company lowers its full-year revenue forecast.
Teva (TEVA) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Pricing erosion in U.S. generics market and rapid erosion in sales of Copaxone are likely to hurt Teva's (TEVA) sales in Q1.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.14, marking a +0.93% move from the previous day.
Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
While Amgen's (AMGN) growth drugs like Prolia & Xgeva may do well, biosimilar competition and slowdown in sales of mature products are likely to put pressure on sales growth.
Allergan Falls as Supreme Court Dismisses Restasis Litigation
by Zacks Equity Research
Allergan's (AGN) key drug, Restasis' prospects hurt as the U.S. Supreme Court upholds the ruling of a lower court, which invalidated certain patents protecting the drug.
BioDelivery (BDSI) Buys US Rights to Pain Drug for $30M
by Zacks Equity Research
BioDelivery Sciences (BDSI) announces acquisition of U.S. commercial rights to pain drug, Symproic, from Japanese company, Shinogi.
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Teva, Novartis, Merck and AstraZeneca
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU
by Kinjel Shah
Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Novartis & Amgen in Legal Dispute Over Migraine Drug Aimovig
by Zacks Equity Research
Novartis (NVS) sues Amgen as the latter issues termination notice for migraine drug.
Teva's Anti-CGRP Injection Ajovy Gets Approval in Europe
by Zacks Equity Research
Teva's (TEVA) CGRP injection, Ajovy gets marketing approval in the EU after securing approval in the United States last year.
Novartis (NVS) Receives FDA Approval for MS Drug Mayzent
by Zacks Equity Research
Novartis (NVS) obtains FDA approval for Mayzent for the treatment of relapsing forms of MS.
Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
by Zacks Equity Research
Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.
Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
by Zacks Equity Research
The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.
AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA
by Zacks Equity Research
FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.
Teva Pharmaceutical Industries Ltd. (TEVA) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $16.64, marking a +0.79% move from the previous day.
BioDelivery (BDSI) Q4 Earnings In Line, Sales Beat, Stock Up
by Zacks Equity Research
BioDelivery Sciences (BDSI) reports in-line loss in Q4. Sales beat the consensus mark. The company issues encouraging guidance for 2019.
Insys Plunges on Auditor's Concern About Insufficient Funds
by Zacks Equity Research
Insys Therapeutics' (INSY) shares plunge after its auditor raises concerns related to insufficiency of funds to continue operations.
Allergan Announces FDA Acceptance of Migraine Candidate NDA
by Zacks Equity Research
Allergan's (AGN) new drug application seeking approval for its oral anti-CGRP candidate, ubrogepant, as acute treatment for migraine gets FDA acceptance. A decision is expected in Q4.
Teva Pharmaceutical Industries Ltd. (TEVA) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Teva Pharmaceutical Industries Ltd. (TEVA) closed at $15.78, marking a +0.19% move from the previous day.
Lilly's Emgality Gets FDA Priority Review for Cluster Headache
by Zacks Equity Research
Eli Lilly's (LLY) supplemental biologics license application for its migraine drug, Emgality, wins a priority review from the FDA for treating episodic cluster headache in adults.
Mylan (MYL) Q4 Earnings & Revenues Miss Estimates, Stock Down
by Zacks Equity Research
Mylan (MYL) Q4 earnings and sales miss estimates due to persistent challenges in the North America segment. The guidance for 2019 was weak as well.